Taipei Medical University Institutional Repository:Item 987654321/5209
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 45073/58249 (77%)
Visitors : 2380353      Online Users : 151
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/5209


    题名: (1)嘗試以陽離子交換樹脂層析法純化豬精漿內已知的精子活動力抑制蛋 白SMI之研究;(2)維生素K3對人類子宮頸癌細胞之抗癌活性及作用機轉之 研究
    (1)The Utilization of Cation Exchanger to Purify Sperm Motility Inhibitor (SMI) from Porcine Seminal Plasma;(2) The Anitumor Acitivy and Machanistic Study of Vitamin K3 against Human Cervical Carcino
    作者: 孫德萍
    Sun, Te-Ping
    贡献者: 醫學研究所
    关键词: 精子活動力抑制蛋白
    維生素K3
    子宮頸癌細胞
    SMI
    Vitamin K3
    Cervical Carcinoma
    日期: 1996
    上传时间: 2009-09-11 15:26:25 (UTC+8)
    摘要: (一) 精漿 (seminal plasma) 中的物質主要由雄性副性腺的分泌物組成
    ,如精囊 (seminal vesicle),前列腺 (prostate gland) 以及尿道球腺
    (bulbourethal gland) 的分泌物等。SMI (sperm motility inhibitor)
    乃由豬精漿中分離純化,含91個胺基酸,具有抑制公豬精子活動力及降低
    其頭帽反應頻率的蛋白質。今另嘗試以陽離子交換樹脂層析法純化之。利
    用陽離子交換層析柱carboxymethyl cellulose chroma-tography (CM52)
    分離豬精漿液中蛋白質,收集20 mM HEPES,pH 7.9,1 mM EDTA的緩衝沖
    洗液,再以陽離子交換層析柱phosphocellulose chromatography (P11)
    吸附後,在含氯化鉀0~0.1 M之20 mM HEPES,pH 7.9,1 mM EDTA緩衝鹽
    溶液中,可沖提出SMI。純化的蛋白質經濃縮並去除鹽份後,即以SDS-
    PAGE,HPLC及質量質譜分析儀分析。以質量質譜分析儀分析此蛋白質質量
    為 (10,067*1) dalton。證實豬精漿液在經過2次陽離子交換層析純化後
    ,可獲得純化之SMI蛋白質。吾更進一步根據其於體內分布,選用肺炎雙
    球菌測試對其生長能力的影響,結果顯示並無抑制作用。 (二) 維生素
    K3 (VK3,2-甲基-1,4- 奈昆 ) 是兩種天然維生素K1及K2的人工合成類似
    物。VK3對不同囓齒動物及人類腫瘤細胞具有廣泛之抑制生長作用。而且
    已知VK3是維生素K族中最強之抗癌藥。在美及臺已進行第一、二期之臨床
    試驗。以sulforhodamine B (SRB) 染色法得知VK3對人類子宮頸癌SiHa細
    胞株的半致死劑量為37微莫耳濃度。在作用機轉之研究中,發現VK3在
    SiHa細胞中可引起: (1) 細胞週期運轉延遲於S或G2/M期,(2) 改變具細
    胞週期特異性蛋白質之表現或磷酸化之程度,如CDK1激活,Cdc25磷酸
    ,Cyclins A及E。為了闡明VK3直接標的物,以人工合成一段十一個胺
    基酸胜鏈(含遍存於蛋白質酪胺酸磷酸 (protein tyrosine
    phosphatase) 及雙重特異性蛋白質磷酸 (dual specificity protein
    phosphatase) 活化中心)與帶有放射性之VK3作用證明,VK3可和此鏈內
    之cysteine (Cys) 胺基酸結合,使酵素失去活性,但無法與由Cys突變為
    serine (Ser) 的胜鏈結合。VK3可能是目前臨床抗癌藥物中,第一個被
    發現為蛋白質酪胺酸磷酸的抑制劑。上述結果顯示 VK3 可能因與Cdc25
    磷酸之Cys結合,使其活性散失進而使CDK1激活酵素處於高度磷酸化而
    失去活性,導致癌細胞無法進行細胞週期運轉而死亡。
    (PART I): Seminal plasma has been shown to be composed of fluid
    from male accessory sex glands, such as seminal vesicle,
    prostate gland and bulbourethal gland etc. Sperm motility
    inhibitor (SMI) was previously purified from porcine seminal
    plasma as described and the utilization of cation exchanger to
    purify was also tried in this report. SMI was shown to contain
    91 amino acids, and to decrease the sperm motility and its
    frequency of acrosomal reaction rate of spermatozoa.
    Carboxymethyl cellulose chromatography (CM52) was used to
    partial purify SMI protein from porcine seminal plasma. The
    fractions containing SMI protein were obtained in the flow
    through buffer (20 mM HEPES, pH 7.9 and 1mM EDTA; PC buffer) as
    determined by sodium dodecyl sulfate-polyacrylamide gel
    electrophoresis (SDS-PAGE) and reversed-phase high performance
    liquid chromatography (RP-HPLC). After the SMI was checked and
    surely contained in the collected fractions, the
    phosphocellulose chromato-graphy was used for the further
    purification. And then the purified SMI protein was found in the
    gradient PC buffer containing 0 ~ 0.1 M KCl. The result was also
    checked by SDS-PAGE, RP-HPLC and mass spectrophotometer. The
    molecular weight of SMI determined by mass spectrophoto-meter is
    (10,067*1) dalton, which is the same as previously reported by
    others.SMI was identical to b-microseminoprotein and was also
    found in the mucosa of respiratory and digestive tract. The
    Streptococcus pneumonia was chosen to clarify the role of SMI (2
    and 20 mg) in the mucous secretory tissue. No inhibitory effect
    on the growth of Streptococcus pneumonia was found after 24 h
    incubation in a humidified 5 % CO2 incubator. (PART II): Vitamin
    K3 (VK3, 2-methyl-1,4-naphthoquinone) is the synthetic
    derivative of two naturally occuring vitamin K1 and K2. It has
    been shown that VK3 exhibits a broad spectrum of antitumor
    activity in rodent and human tumor cells. Among these three VK
    congeners, VK3 exerts the most toxic effect toward cancer cells.
    A phase I/II clinical trials of VK3 has been performed in both
    U.S. and Taiwan. The IC50 of VK3 against human cervical
    carcinoma SiHa cells is 37 mM as determined by sulforhodamine B
    (SRB) colorimetric assay. In the mechanistic study of VK3*s
    action on SiHa cells, we found that VK3 induces: (1) the cell
    cycle arrest or delayed at the S or G2/M phase, (2) the
    alterations of the expression or phosphorylation status of cell
    cycle specific proteins, such as CDK1, Cdc25 phosphatase,
    Cyclins A and E. For the elucidation of the direct target of
    VK3*s action on cells, the synthesized undecapeptide, containing
    the conserved cysteine (Cys) active domain of protein tyrosine
    phosphatases family and dual specificity protein phosphatases
    family, were incubated with 3H-VK3 in vitro. VK3 was found to
    bind directly to the peptide containing Cys residue but not to
    the mutant couenterpartner containing Cys mutated to serine
    (Ser). Among the clinically used anticancer drugs, VK3 might be
    the first drug that acts as an inhibitor of protein tyrosine
    phosphatases. Our results suggest that binding of VK3 to the
    Cys residue at the active site of Cdc25 phosphatase generates
    the hyperphosphorylated inactive form of CDK1 which in turn
    induces cell cycle arrest, leading to the cell death.
    数据类型: thesis
    显示于类别:[Graduate Institute of Medical Sciences] Dissertation/Thesis

    文件中的档案:

    档案 描述 大小格式浏览次数
    摘要.doc40KbMicrosoft Word412检视/开启
    摘要.pdf126KbAdobe PDF414检视/开启
    摘要.ppt123KbMicrosoft Powerpoint624检视/开启
    摘要.ps627KbPostscript177检视/开启


    在TMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    著作權聲明 Copyright Notice
    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏,包含體系內各式學術著作及學術產出。秉持開放取用的精神,提供使用者進行資料檢索、下載與取用,惟仍請適度、合理地於合法範圍內使用本平台之內容,以尊重著作權人之權益。商業上之利用,請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台,視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例,並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者,煩請權利人通知本平台維護人員([email protected]),將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈